iRhythm Technologies IRTC recently announced initial research findings on the post-market, real-world performance of the Zio monitor, IRTC’s next-generation Zio long-term continuous monitoring (LTCM) ...

iRhythm is launching its next generation long-term ambulatory cardiac monitor in the U.S. The new Zio monitor is a prescription-only ECG monitor, which is an integral part of the Zio LTCM service. The ...

A new study from the Scripps Translational Science Institute, published in the American Journal of Medicine, shows that iRhythm's Zio patch, a wireless adhesive heart monitor patch, detects more ...

Aetna will now reimburse for iRhythm's ZIO Patch, a continuous long-term heart monitor worn on an adhesive patch. The insurer recently updated its Clinical Policy Bulletin on cardiac event monitors, ...

SAN FRANCISCO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (IRTC) (NASDAQ:IRTC) today announced initial research findings on post-market, real-world performance of Zio ® monitor, its ...

Zio ECG monitoring system is the only fourteen-day cardiac monitoring service in its category to receive Japanese regulatory approval as an improved device without a clinical trial Zio ECG monitoring ...

RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac ...

SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the commercial launch in Japan of its Zio ® long-term continuous ECG monitoring (LTCM) system, ...

MADRID -- Remote screening yielded new cases of atrial fibrillation (Afib or AF) in the general population that otherwise would have gone undetected and untreated, according to the AMALFI trial in the ...

Findings in a younger, commercially insured population build on Medicare-based CAMELOT results, expanding the generalizability of Zio LTCM's clinical impact across patient groups. Latest data showed ...